BridgeMD
Preoperative Indocyanine Green administration increases intraoperative detection of Liver Tumors in Imaging-guided surgery. A phase IV clinical trial.
EU CTIS ID: 2023-508316-27-00
What this study is testing
To analyze the detection of liver tumors using indocyanine green fluorescence uptake in combination with intraoperative ultrasonography and preoperative imaging test To develop a machine-learning algorithm to detect liver tumors with indocyanine green by photographic analysis.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients with liver tumors with an indication for minimally invasive surgery, evaluated by the hospital’s multidisciplinary liver tumor board (MDTB).
- Preoperative imaging test (contrast-enhanced liver MRI, multiphasic contrast-enhanced abdominal CT, or contrast-enhanced PET-CT) performed prior to the surgical intervention according to usual clinical practice of each site.
- ≥18 years old
- Absence of exclusion criteria and able to provide consent for data collection and analysis
You likely can't join if
- Emergency surgery
- Patients in which ICG is contraindicated (one condition will be enough for excluding the patient): 1. previous history of iodine hypersensitivity; 2. patients with renal failure (GFR <60 mL/min/1.73 m2); 3 uremic syndrome; 4. clinical hyperthyroidism; 5. autonomic thyroid adenomas; or 6. focal and diffuse autonomic abnormalities of the thyroid gland.
- Previous liver surgery
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.